UBS Group
VYNE icon

UBS Group’s VYNE Therapeutics VYNE Stock Holding History

UBS Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Buy
179,784
+117,023
+186% +$68.3K ﹤0.01% 6969
2025
Q4 		$36.4K Buy
62,761
+57,189
+1,026% +$23K ﹤0.01% 7399
2025
Q3 		$1.87K Buy
+5,572
New +$3.65K ﹤0.01% 9268
2025
Q2 		– Sell
-7,576
Closed -$12K – 10881
2025
Q1 		$12K Buy
7,576
+6,945
+1,101% +$17.1K ﹤0.01% 8521
2024
Q4 		$2.11K Buy
631
+617
+4,407% +$1.61K ﹤0.01% 9109
2024
Q3 		$26 Sell
14
-25,044
-100% -$47.5K ﹤0.01% 9292
2024
Q2 		$49.4K Buy
25,058
+25,042
+156,513% +$62.5K ﹤0.01% 6700
2024
Q1 		$49 Sell
16
-830
-98% -$1.79K ﹤0.01% 8930
2023
Q4 		$1.97K Buy
846
+662
+360% +$2.06K ﹤0.01% 8185
2023
Q3 		$744 Sell
184
-902
-83% -$3.94K ﹤0.01% 8303
2023
Q2 		$4.45K Buy
1,086
+721
+198% +$3.84K ﹤0.01% 7532
2023
Q1 		$1.12K Sell
365
-2,672
-88% -$9.6K ﹤0.01% 8804
2022
Q4 		$8.2K Buy
3,037
+2,456
+423% +$9.82K ﹤0.01% 8806
2022
Q3 		$2K Sell
581
-1
-0.2% -$6 ﹤0.01% 9783
2022
Q2 		$4K Buy
582
+568
+4,057% +$4.76K ﹤0.01% 9147
2022
Q1 		$0 Hold
14
– – ﹤0.01% 10965
2021
Q4 		$0 Sell
14
-211
-94% -$4.53K ﹤0.01% 10757
2021
Q3 		$6K Sell
225
-180
-44% -$6.98K ﹤0.01% 8454
2021
Q2 		$26K Buy
405
+35
+9% +$2.77K ﹤0.01% 7084
2021
Q1 		$46K Sell
370
-1,700
-82% -$247K ﹤0.01% 6648
2020
Q4 		$236K Buy
2,070
+777
+60% +$97.6K ﹤0.01% 5142
2020
Q3 		$155K Sell
1,293
-134
-9% -$15.6K ﹤0.01% 4943
2020
Q2 		$178K Buy
1,427
+861
+152% +$117K ﹤0.01% 4886
2020
Q1 		$109K Buy
566
+300
+113% +$94.1K ﹤0.01% 5222
2019
Q4 		$89K Buy
266
+83
+45% +$27.7K ﹤0.01% 6067
2019
Q3 		$59K Buy
183
+119
+186% +$38.4K ﹤0.01% 6106
2019
Q2 		$28K Buy
64
+37
+137% +$18.3K ﹤0.01% 6390
2019
Q1 		$15K Sell
27
-93
-78% -$44.6K ﹤0.01% 6553
2018
Q4 		$36K Buy
+120
New +$53.7K ﹤0.01% 6354
2018
Q3 		– Sell
-11
Closed -$7K – 8298
2018
Q2 		$7K Buy
11
+6
+120% +$4.66K ﹤0.01% 7352
2018
Q1 		$14K Buy
+5
New +$12.2K ﹤0.01% 6671

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group's VYNE Position: Q1 2026 in Review

UBS Group increased its VYNE Therapeutics (VYNE) stake by 186% in Q1 2026, buying an estimated $68.3K and bringing the position to 179,784 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #6969.

UBS Group first reported a position in VYNE in Q1 2018 and has held it in 31 quarters since. The position peaked at $236K in Q4 2020. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • UBS Group held 179,784 shares of VYNE Therapeutics worth $108K as of Q1 2026.
  • UBS Group bought 117,023 VYNE Therapeutics shares in Q1 2026, an estimated $68.3K.
  • VYNE Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6969 holding.
  • UBS Group first reported a position in VYNE Therapeutics in Q1 2018 and has held it in 31 quarters since.
  • UBS Group's VYNE Therapeutics position peaked at $236K in Q4 2020.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.